Clinical Trials Sponsored by Netherlands Institute for Pigment Disorders

Total 261 results

Netherlands Institute for Pigment Disorders

Withdrawn

Fractional Laser in Combination With UVB Therapy in Vitiligo Patients

Vitiligo

Netherlands
Netherlands Institute for Pigment Disorders

Completed

Fractional Laser as Treatment Option for Various Pigment Disorders (Fractional-3)

Pigmentation Disorder

Netherlands
Netherlands Institute for Pigment Disorders

Terminated

Fractional Laser Assisted Topical Anesthesia

Cicatrix

Netherlands
Netherlands Institute for Pigment Disorders

Completed

Fractional Laser Assisted Delivery of Anesthetics IIIb

Local Anesthesia of the Skin
Netherlands Institute for Pigment Disorders

Completed

Fractional Laser as Treatment Option for Various Pigment Disorders (fractional-2)

Pigmentation Disorder
Netherlands Institute for Pigment Disorders
Avita Medical

Completed

Autologous Cell Suspension Grafting Using ReCell in Vitiligo and Piebaldism Patients

Piebaldism | Segmental Vitiligo

Netherlands
Netherlands Institute for Pigment Disorders
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Completed

Fractional Laser Assisted Delivery of Anesthetics III

Local Anesthesia of the Skin

Netherlands
Netherlands Institute for Pigment Disorders
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Completed

Fractional Laser Assisted Delivery of Anesthetics

Local Anesthesia of the Skin.

Netherlands
Netherlands Institute for Pigment Disorders
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA); Avita Medical

Terminated

ReNovaCell in Non-segmental Vitiligo

Vitiligo | Non-segmental Vitiligo

Netherlands
Institute for Neurodegenerative Disorders

Terminated

Brain Imaging Study in Subjects With Alzheimer Disease in Comparison to Healthy Subjects

Alzheimer's Disease

United States
Institute for Neurodegenerative Disorders

Terminated

Single Photon Emission Computed Tomography (SPECT) Imaging Study to Develop a Biomarker for Alzheimer's Disease

Alzheimer's Disease

United States
Institute for Neurodegenerative Disorders

Completed

The Study of the Impact of Disclosing Imaging Study Information to Trial Participants

Parkinson | Parkinsonian Syndrome

United States
Institute for Neurodegenerative Disorders

Completed

A Study of the Sense of Smell in Relatives of Parkinson's Disease Patients

Parkinson Disease | Parkinsonian Syndrome

United States
Institute for Neurodegenerative Disorders

Completed

Evaluation of [123I] AV51 and SPECT as a Marker of Beta-amyloid Protein Deposition in Subjects With Alzheimer Disease in Comparison to Healthy Subjects

Alzheimer Disease

United States
Institute for Neurodegenerative Disorders

Completed

A PET Brain Imaging Study of mGluR5 in Subjects With Neuropsychiatric Conditions (FPEB)

Parkinson Disease | Alzheimer Disease | Mild Cognitive Impairment | Fragile X Syndrome | Huntington Disease | Autistic Spectrum Disorders

United States
Institute for Neurodegenerative Disorders

Completed

Evaluation of 123-I Iodobenzovesamicol (IBVM) and SPECT Imaging of Healthy Subjects and Patients With Alzheimer Disease (IBVM001)

Parkinson Disease | Alzheimer Disease

United States
Institute for Neurodegenerative Disorders

Completed

Evaluation of [18F]MK-9470 as a Brain Tracer of Cannabinoid-1 Receptor in Parkinson's Disease and Healthy Subjects (MK9470)

Parkinson Disease

United States
Institute for Neurodegenerative Disorders

Terminated

Evaluation of [18F] PBR06 and PET as a Marker of Inflammation in Subjects With Neurological Conditions (PBR06)

Multiple Sclerosis | Parkinson Disease | Alzheimer Disease

United States
Institute for Neurodegenerative Disorders

Terminated

Evaluation of [123I]CLINDE and SPECT as a Marker of Inflammation in Subjects With PD or AD and in Healthy Subjects (CLINDE)

Multiple Sclerosis | Parkinson Disease | Alzheimer Disease | Healthy Controls

United States
Institute for Neurodegenerative Disorders

Completed

Evaluation of [18F] FMH3 and PET as a Marker of Histamine-3 Receptor Activity in Subjects With AD Compared w/ HC (FMH3)

Alzheimer Disease

United States
Institute for Neurodegenerative Disorders

Completed

Evaluation of [18F] FEPPA and PET Imaging as a Marker of Inflammation in Subjects With Neurological Conditions

Multiple Sclerosis | Parkinson Disease | Alzheimer Disease

United States
Institute for Neurodegenerative Disorders

Terminated

Evaluation of [123I] AV94 and SPECT in Subjects With Alzheimer Disease in Comparison to Healthy Subjects (AV94)

Alzheimer Disease

United States
Institute for Neurodegenerative Disorders

Terminated

Safety and Efficacy of Positron Emission Tomography Imaging With MNI-513

Alzheimer Disease

United States
Institute for Neurodegenerative Disorders

Terminated

Evaluation of [123I] MNI-340 and SPECT as a Marker of Beta-Amyloid Protein Deposition

Alzheimer's Disease

United States
Institute for Neurodegenerative Disorders

Completed

Evaluation of [123I]MNI-420 and SPECT as a Marker of the Adenosine A2a Receptor in PD, HD and Healthy Subjects. (MNI-420)

Parkinson Disease | Huntington Disease

United States
Institute for Neurodegenerative Disorders

Completed

Research Involving Subjects With Parkinson's Disease, Alzheimer Disease and Healthy Controls

Parkinson Disease | Alzheimer Disease

United States
Institute for Neurodegenerative Disorders

Completed

Evaluation of [18F]MPPF as a Brain Tracer of Serotonin Receptor 5HT1a (MPPF)

Parkinson Disease

United States
Institute for Neurodegenerative Disorders

Completed

Evaluation of [18F] PBR111 and PET as a Marker of Inflammation in Subjects With Neurological Conditions (PBR111)

Alzheimer Disease

United States
Institute for Neurodegenerative Disorders

Terminated

Evaluation of [123I] AV151 and SPECT in Subjects w/ AD in Comparison to Healthy Subjects (AV151)

Alzheimer Disease

United States
Institute for Neurodegenerative Disorders
Biogen

Completed

Study to Evaluate the Feasibility of [18F]Florbetapir PET for Assessment in MS Patients

Multiple Sclerosis

United States
GGZ Buitenamstel
Netherlands Institute for Brain Research, Amsterdam, The Netherlands.

Terminated

Light Therapy for Elderly Depression

Major Depressive Disorder

Netherlands
Michael J. Fox Foundation for Parkinson's Research
Institute for Neurodegenerative Disorders

Recruiting

PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort (PPMI)

Parkinson Disease

United States, Canada, Spain, Israel, Austria, Germany, Greece, Italy, Netherlands, Nigeria, United Kingdom, Luxembourg
Michael J. Fox Foundation for Parkinson's Research
Institute for Neurodegenerative Disorders

Completed

PPMI Tau PET Imaging

Parkinson Disease

United States
Molecular NeuroImaging
Institute for Neurodegenerative Disorders

Completed

ALTROPANE® SPECT Imaging in Patients With Parkinson Disease

Parkinson Disease

United States
Institute for Neurodegenerative Disorders
Molecular NeuroImaging

Completed

Safety and Efficacy of Positron Emission Tomography (PET) Imaging With MNI-558 (MNI-558)

Alzheimer Disease

United States
Molecular NeuroImaging
Institute for Neurodegenerative Disorders

Completed

Use of [123I] AV39 and SPECT Imaging as a Marker of Protein Disposition in Subjects With Alzheimer Disease Compared to Healthy Subjects

Alzheimers Disease

United States
Institute for Neurodegenerative Disorders
Molecular NeuroImaging

Terminated

Assessment of the Effect of Sertaline on the Specific Binding of 123-I MZINT in Healthy Subjects (mZINT)

Depression

United States
Institute for Neurodegenerative Disorders
Molecular NeuroImaging

Terminated

Evaluation of [123I] MNI-330 and SPECT as a Marker of Beta-amyloid Protein Deposition

Alzheimer Disease

United States
Institute for Neurodegenerative Disorders
Molecular NeuroImaging

Completed

A Study of Neurophysiologic Changes in Individuals With Parkinson's Disease

Parkinson's Disease | Parkinsonian Syndrome

United States
Institute for Neurodegenerative Disorders
Molecular NeuroImaging

Terminated

Assessment of the Biodistribution and Safety of 123-I MZINT in Healthy Subjects and Parkinson Disease Patients

Parkinson Disease

United States
Molecular NeuroImaging
Institute for Neurodegenerative Disorders

Completed

Evaluation of [123I] AV83 and SPECT in Patients With Alzheimer Disease in Comparison to Healthy Controls

Alzheimers Disease

United States
Institute for Neurodegenerative Disorders
Molecular NeuroImaging

Completed

Evaluation of [123I] MNI-187 and SPECT in Patients With Alzheimers Disease in Comparison to Healthy Subjects

Alzheimers Disease

United States
Molecular NeuroImaging
Institute for Neurodegenerative Disorders

Completed

Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects

Alzheimer's Disease (AD) | Tauopathies | Parkinson's Disease (PD) | Progressive Supranuclear Palsy (PSP) | Chronic Traumatic Encephalopathy (CTE) | Frontal Temporal Dementia (FTD) | Pick's Disease

United States
Institute for Neurodegenerative Disorders
Molecular NeuroImaging

Completed

Study of Individuals With Parkinson's Symptoms But in Whom There is Diagnostic Uncertainty

Parkinsonian Syndrome

United States
Institute for Neurodegenerative Disorders
Molecular NeuroImaging

Completed

Biodistribution and Safety of a Radiopharmaceutical in Healthy Subjects

Neurodegenerative Diseases

United States
Westwood Institute for Anxiety Disorders, Inc

Unknown

Study of Patients With Body Image Issues Treated With 2 Different Behavioral Interventions (BDD)

Body Dysmorphic Disorders

United States
Institute for Neurodegenerative Disorders
GE Healthcare; Pfizer

Completed

Study of the Effects of Dopaminergic Medications on Dopamine Transporter Density in Subjects With Parkinson's Disease

Parkinson Disease | Parkinsonian Syndrome

Spain, Austria, Germany, Italy
The Netherlands Cancer Institute
ZonMw: The Netherlands Organisation for Health Research and Development

Recruiting

Dedicated MR Imaging vs Surgical Staging of Peritoneal Carcinomatosis in Colorectal Cancer (DISCO)

MRI | Colorectal Cancer | Peritoneal Carcinomatosis

Netherlands
Utrecht Institute for Pharmaceutical Sciences
Royal Netherlands Navy

Completed

Effects of Levocetirizine and Hydroxyzine on Cognitive and Psychomotor Functioning During Simulated Diving

Healthy Volunteers

Netherlands
Ken Marek, MD
Institute for Neurodegenerative Disorders

Completed

Study to Identify Clinical, Imaging and Biologic Markers of Parkinson Disease Progression (PPMI)

Parkinson Disease

United States, Spain, Israel, Norway, Germany, Italy, United Kingdom, France, Austria, Australia, Greece

Clinical Trials Sponsored by Netherlands Institute for Pigment Disorders

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Romania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations